Medtide Inc (3880) Fair Value & Analysis
Healthcare · HK · Market cap HK$3.1B
Fair value as of: Aug 13, 2026
From 26 valuation models · updated 3 days ago
Fair value updated Aug 13, 2026, revised from HK$30.28 to HK$28.89 (−4.6%) since Aug 6, 2026. Share price −11.3% over the past month.
A solid business, screening 34% undervalued on our models.
What matters now
- Solid quality (69/100) at a price below fair value, the discount is the argument here, not the business quality.
- Our model range runs from HK$21.36 (bear) to HK$36.18 (bull), base HK$28.89. The closer the price sits to the lower half, the larger the margin of safety.
- Quality 69/100 (solid quality) with high evidence: the data supports the verdict.
Price vs Fair Value (13 months)
White line = price, green steps = our fair value per fiscal year. As of Aug 13, 2026.
How to read this chart
13‑month range HK$19.63 – HK$40.64 · fair‑value band HK$21.36 – HK$36.18 · the HK$21.64 price screens below the HK$28.89 fair value. As of Aug 13, 2026.
Analysis
Medtide Inc (3880) currently trades at HK$21.64, while our model-based Fair Value estimate is HK$28.89, implying the stock looks roughly 33.5% undervalued today. The Quality Score stands at 69/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.
Over the trailing twelve months, Medtide Inc generated revenue of HK$570M at a net margin of 38.1%. Revenue grew 29.2% year over year. It earns a return on equity of 22.8%. Net debt stands at HK$41.5M. Fundamentals as of Aug 13, 2026
Our scenario range runs from HK$21.36 (bear case) to HK$36.18 (bull case); at HK$21.64, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 48% below its 52-week high and 14% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -47% fair-value upside, at 34%, 3880 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 26 models by family
Widest divergence: Growth Earnings (HK$49.28) versus Dividend Discount (HK$2.05). Highest evidence: Growth DCF (80).
Notify me when 3880 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 67 · Market factors (momentum, volatility) 24
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Medtide Inc., a contract research, development, and manufacturing company, provides early-stage discovery, pre-clinical research, clinical development, and commercial-stage production services. It offers peptide new chemical entity discovery synthesis, manufacturing, and control development and commercial manufacturing services.
Full company description
Medtide Inc., a contract research, development, and manufacturing company, provides early-stage discovery, pre-clinical research, clinical development, and commercial-stage production services. It offers peptide new chemical entity discovery synthesis, manufacturing, and control development and commercial manufacturing services. The company focuses on developing oral and/or injectable glucagon, such as peptide-1 (GLP-1) molecule products. Its research and development technology platforms include OmniPeptSynth, PeptiConjuX, PeptiNuclide LinkTech, GreenSynth Innovations, and Impurity Screening. It serves customers in China, the United States, Japan, Europe, South Korea, and Australia. The company was formerly known as Taide Pharmaceutical (Zhejiang) Co., Ltd and changed its name to Medtide Inc. in February 2023. Medtide Inc. was incorporated in 2020 and is headquartered in Hangzhou, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Medtide Inc reported revenue of HK$570M in FY2025 versus HK$282M in FY2021, a compound +19.2%/yr. Reported net income was HK$217M in FY2025, compounding +28.3%/yr from FY2021.
Watch 3880: get an alert when its fair value changes →
Peer Group
Biotechnology · 605 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Biotechnology median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | $525.73 | $278.78 | -47% |
| Regeneron Pharmaceuticals, Inc REGN | $797.99 | $594.40 | -26% |
| Samsung Biologics Co 207940 | 1,549,000 KRW | 1,055,793 KRW | -32% |
| Celltrion, Inc 068270 | 202,000 KRW | 74,519 KRW | -63% |
| WuXi Biologics (Cayman) Inc 2269 | HK$45.70 | HK$30.58 | -33% |
| Innovent Biologics, Inc 1801 | HK$95.55 | HK$19.68 | -79% |
| Genmab A/S GMAB | kr 2,037 | kr 250.07 | -88% |
| Sino Biopharmaceutical Limited 1177 | HK$4.87 | HK$3.37 | -31% |
| RemeGen Co 688331 | ¥131.87 | ¥23.19 | -82% |
| ALTEOGEN Inc 196170 | 314,000 KRW | 39,476 KRW | -87% |
Compare Medtide Inc with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Medtide Inc (3880) overvalued or undervalued?
What is the fair value of 3880?
What is the quality score of 3880?
What is the revenue of Medtide Inc (3880)?
What is the net profit margin of 3880?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Medtide Inc and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.